BPC-157
KPV vs BPC-157: Two Gut Peptides Compared on Mechanism and Evidence
SB
· 9 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
KPV and BPC-157 are both studied in colitis models, and that is most of what they share. KPV is a three-residue fragment (Lys-Pro-Val) from the end of the hormone α-MSH. It is reported to enter gut cells through the PepT1 transporter and dampen inflammatory signalling. BPC-157 is a 15-residue sequence derived from a gastric juice protein. It is reported to work through blood-vessel growth and the nitric oxide system. Both have animal evidence only, with essentially no controlled human data. Neither is approved anywhere.

Two very different molecules
| KPV | BPC-157 | |
|---|---|---|
| Length | 3 amino acids | 15 amino acids |
| Sequence | Lys-Pro-Val | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | C-terminal residues 11–13 of α-melanocyte-stimulating hormone | Partial sequence of a protein from human gastric juice |
| First described | 1989, as an anti-inflammatory α-MSH fragment | 1990s, Sikiric group, Zagreb |
| Proposed entry or target | Taken up by PepT1, the intestinal di- and tripeptide transporter; no receptor identified | No receptor identified |
| Proposed downstream mechanism | Inhibition of NF-κB and MAP kinase signalling; lower pro-inflammatory cytokines | Interaction with the nitric oxide system; angiogenesis; restoring blood supply to injured tissue |
| Gut models studied | DSS colitis, TNBS colitis, T-cell transfer colitis in mice | Cysteamine colitis, ischaemic colitis, anastomoses and fistulas in rats |
| Main research groups | Dalmasso, Merlin and colleagues; Kannengiesser and colleagues | Sikiric laboratory (Zagreb), which produced most of the literature |
| Human evidence | None published | Three small uncontrolled studies, 30 people in total, none in the gut; an early IBD programme with no peer-reviewed efficacy results we could find |
| Regulatory status | Not approved anywhere | Not approved anywhere; prohibited in sport under WADA's S0 section |
The size difference is not a detail. A tripeptide is the kind of molecule the gut's nutrient transporters evolved to carry, and the KPV story depends on that. A 15-residue peptide is far too large for PepT1. The BPC-157 literature instead emphasises the compound's reported stability in gastric juice, which is where its name, "body protection compound", and its origin come from (PMID 22300085).
How is KPV proposed to work in the gut?
Dalmasso and colleagues set out the mechanism in 2008. In human intestinal epithelial cells and T cells, nanomolar KPV inhibited NF-κB and MAP kinase inflammatory signalling and reduced pro-inflammatory cytokine secretion. Uptake experiments showed KPV is carried into cells by PepT1. That transporter is normally found in the small intestine and is induced in the colon during inflammatory bowel disease. In two mouse colitis models, DSS and TNBS, KPV lowered pro-inflammatory cytokine expression (PMID 18061177).
Kannengiesser and colleagues, a separate group, reported the same year that KPV sped recovery and reduced inflammatory infiltrates in DSS colitis and in T-cell transfer colitis. In mice with a non-functional melanocortin-1 receptor, KPV still rescued all treated animals from death during DSS colitis. That suggests its effect is at least partly independent of the receptor its parent hormone uses (PMID 18092346). This is why KPV is described as having "half a mechanism". How it gets in is well specified. What it binds once inside is not. The fuller account is in KPV and the colitis literature.
Later work treats KPV mainly as cargo for delivery systems. Laroui and colleagues loaded it into nanoparticles inside a polysaccharide gel built to collapse in the colon. They reported protection in DSS colitis at a concentration 12,000-fold lower than free KPV with similar efficacy (PMID 19909746). Xiao and colleagues used hyaluronic-acid-coated nanoparticles aimed at colonic epithelial cells and macrophages (PMID 28143741). The fact that so much engineering went into getting KPV to the colon tells you delivery, not activity, is the limiting problem.
How is BPC-157 proposed to work in the gut?
The BPC-157 account centres on blood supply and the nitric oxide system rather than on an immune pathway. Sikiric's group describes it as interacting with the NO system, protecting endothelium and promoting angiogenesis. They also report that it stimulated expression of early growth response 1, a gene involved in cytokine and growth-factor production and early collagen formation (PMID 22300085).
Their colitis models are different in kind from KPV's. In rats with cysteamine-induced colitis and a colon-to-colon anastomosis, the authors reported that both lesions failed to close in controls and closed in BPC-157-treated animals (PMID 24304574). In an ischaemic colitis model, BPC-157 given at a blood-deprived colon segment rapidly increased visible vessels and collateral connections. It normalised malondialdehyde and nitric oxide levels in colon tissue, and counteracted the effects of an NO-synthase inhibitor and of L-arginine (PMID 29358856). The same group has published on fistulas, short bowel and anastomoses. A 2024 review collects the anastomosis work (PMID 39204186).
So the models differ, and they are not interchangeable. KPV was tested mainly in immune-driven mouse colitis, scored by cytokines and histology. BPC-157 was tested mainly in rat injury and ischaemia models, scored by healing and vascular response. A head-to-head comparison in one model has not been published.
How far has the evidence for each one got?
KPV: no human data. No controlled or uncontrolled human study of KPV in the gut, or in any other condition, has been published. The intestinal literature is two 2008 mouse papers plus delivery-system work built on them.
BPC-157: very little human data, none of it in the gut, and none of it controlled. A 2026 systematic review searched for any human study of BPC-157. It found three, with 30 participants in total: a retrospective series in knee pain, a retrospective pilot in interstitial cystitis, and a two-person safety pilot. All were judged to be of poor methodological quality, and certainty of evidence was rated very low (PMID 42885452). Sikiric's group has described a clinical programme in inflammatory bowel disease under the code PL 14736 as having reached phase II (PMID 22300085). We found no peer-reviewed efficacy results from it.
Who did the work. Most of the BPC-157 literature comes from one laboratory, and most of the KPV gut literature from two groups in a single year. In both cases independent replication is thin. That matters more than the direction of the results. Why that is the first thing to check is explained in how to read a peptide study.
Regulatory status
Neither peptide is approved by Health Canada, the FDA or the EMA for any indication. Neither has an orphan designation or a registration programme with published results. BPC-157 has no approval anywhere, which places it under the World Anti-Doping Agency's S0 "non-approved substances" section. That is explained in are peptides banned in sport.
Where to read further
The connective-tissue thread of BPC-157, where most of its reputation comes from, is in BPC-157 and connective tissue. Its comparison with another repair peptide is in BPC-157 vs TB-500. KPV's airway literature is in KPV and respiratory research. The two peptides appear together, with GHK-Cu and TB-500, in a four-component blend described in inside the KLOW blend. The copper peptide's own hair literature is in GHK-Cu and hair. Nothing here is medical, dosing, or therapeutic guidance.
Supplied here for laboratory use: KPV and BPC-157. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
Frequently asked questions
Is KPV or BPC-157 better studied for colitis? Neither has human gut data, so "better" can only mean more animal work. BPC-157 has the larger literature, almost all from one laboratory, across injury, ischaemia, anastomosis and fistula models in rats. KPV has a narrower but more mechanistically specific literature: PepT1 uptake and NF-κB inhibition in immune-driven mouse colitis, from two groups.
Do KPV and BPC-157 work the same way? No. KPV is proposed to enter intestinal cells through the PepT1 transporter and reduce inflammatory signalling inside them. BPC-157 is proposed to act through the nitric oxide system and blood-vessel growth, restoring blood supply to injured tissue. Neither has an identified receptor, and the two have not been compared directly in any published study.
Why does KPV's small size matter? Because its proposed mechanism depends on it. PepT1, the transporter that absorbs dietary di- and tripeptides, carries KPV into gut cells. Its parent hormone, α-MSH, is thirteen residues and too large for that transporter. BPC-157, at fifteen residues, is also far too large for PepT1, so the uptake argument made for KPV does not apply to it.
Has BPC-157 been tested in people with inflammatory bowel disease? Its developers have described an early clinical programme in inflammatory bowel disease under the code PL 14736, reaching phase II. We found no peer-reviewed efficacy results from it. A 2026 systematic review found only three human studies of BPC-157 of any kind, 30 people in total, none in the gut and none controlled.
Are KPV and BPC-157 legal in Canada? Both are sold here as research chemicals for laboratory use only. Neither is an approved drug in Canada, and neither is sold for human use. BPC-157 is also covered by the World Anti-Doping Agency's non-approved substances section, which matters to anyone subject to anti-doping rules.
Selected Research References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. pubmed.ncbi.nlm.nih.gov/18061177
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. pubmed.ncbi.nlm.nih.gov/18092346
- Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843-853. pubmed.ncbi.nlm.nih.gov/19909746
- Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012;19(1):126-132. pubmed.ncbi.nlm.nih.gov/22300085
- Klicek R, Kolenc D, Suran J, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013;64(5):597-612. pubmed.ncbi.nlm.nih.gov/24304574
- Duzel A, Vlainic J, Antunovic M, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World J Gastroenterol. 2017;23(48):8465-8488. pubmed.ncbi.nlm.nih.gov/29358856
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). pubmed.ncbi.nlm.nih.gov/42885452
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
